Key result
Admission NT-proBNP ≥300 pg/ml links to worse COVID-19 pneumonia severity and ~9% mortality.
Why the study?
The study investigated the association between plasma NT-proBNP level at admission and the severity of COVID-19 pneumonia.
Does an elevated NT-proBNP level at admission correlate with pneumonia severity and adverse clinical outcomes in patients with COVID-19?
Population
91 consecutive patients with confirmed COVID-19 pneumonia in Wuhan
Comparison
NT-proBNP levels >=300 pg/ml vs <300 pg/ml
Design
Retrospective single-centre cohort study
Authors
Loading...
May flag higher-risk COVID-19 pneumonia cases; leaves open utility for risk stratification or heart-failure screening pending prospective data.
Cohort (n=91)
No
Does an elevated NT-proBNP level at admission correlate with pneumonia severity and adverse clinical outcomes in patients with COVID-19?
Absolute Event Rate: 8.7% vs 0%
p-value: p=0.062
Elevated plasma NT-proBNP levels at admission in COVID-19 patients correlate with pneumonia severity and may indicate a higher risk of adverse clinical events, suggesting a role for early heart failure screening.
Wang et al. (2021) conducted a cohort in COVID-19 pneumonia (n=91). NT-proBNP ≥300 pg/ml vs. NT-proBNP <300 pg/ml was evaluated on Mortality (p=0.062). Admission NT-proBNP levels ≥300 pg/ml in COVID-19 patients were associated with greater pneumonia severity and a trend toward higher mortality (8.7% vs 0%, p=0.062) compared to levels <300 pg/ml.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: